Comparative Pharmacology
Head-to-head clinical analysis: MAXAIR versus XTRELUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXAIR versus XTRELUS.
MAXAIR vs XTRELUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular cAMP.
Selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules, reducing glucose reabsorption and lowering blood glucose levels.
2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.
XTRELUS (luseogliflozin) 2.5 mg orally once daily, increased to 5 mg once daily if needed.
None Documented
None Documented
3.5–4.0 hours; clinically, this supports dosing every 4–6 hours as needed.
The terminal elimination half-life is approximately 12 hours in patients with normal renal function. In patients with moderate renal impairment (CrCl 30-50 mL/min), half-life is prolonged to 20-24 hours, necessitating dose adjustment.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; fecal excretion is minimal (<5%).
Renal excretion accounts for approximately 65% of the administered dose as unchanged drug, with an additional 20% as metabolites. Biliary/fecal excretion accounts for the remaining 15%, primarily as metabolites.
Category C
Category C
Bronchodilator
Bronchodilator